Works matching IS 13406868 AND DT 2023 AND VI 30 AND IP 3
Results: 14
Phase 1 study of oral selective estrogen receptor degrader (SERD) amcenestrant (SAR439859), in Japanese women with ER-positive and HER2-negative advanced breast cancer (AMEERA-2).
- Published in:
- Breast Cancer (13406868), 2023, v. 30, n. 3, p. 506, doi. 10.1007/s12282-023-01443-8
- By:
- Publication type:
- Article
Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at < 1% in the tumor region.
- Published in:
- Breast Cancer (13406868), 2023, v. 30, n. 3, p. 497, doi. 10.1007/s12282-023-01442-9
- By:
- Publication type:
- Article
Comparing survival outcomes between neoadjuvant and adjuvant chemotherapy within breast cancer subtypes and stages among older women: a SEER-Medicare analysis.
- Published in:
- Breast Cancer (13406868), 2023, v. 30, n. 3, p. 489, doi. 10.1007/s12282-023-01441-w
- By:
- Publication type:
- Article
Construction of a prognostic risk assessment model for HER2 + breast cancer based on autophagy-related genes.
- Published in:
- Breast Cancer (13406868), 2023, v. 30, n. 3, p. 478, doi. 10.1007/s12282-023-01440-x
- By:
- Publication type:
- Article
Severity and risk factors of interval breast cancer in Queensland, Australia: a population-based study.
- Published in:
- Breast Cancer (13406868), 2023, v. 30, n. 3, p. 466, doi. 10.1007/s12282-023-01439-4
- By:
- Publication type:
- Article
Dynamic network biomarker to determine the critical point of breast cancer stage progression.
- Published in:
- Breast Cancer (13406868), 2023, v. 30, n. 3, p. 453, doi. 10.1007/s12282-023-01438-5
- By:
- Publication type:
- Article
ER–/PR+ breast cancer is controlled more effectively with an inflammatory inhibitor than hormonal inhibitor.
- Published in:
- Breast Cancer (13406868), 2023, v. 30, n. 3, p. 436, doi. 10.1007/s12282-023-01437-6
- By:
- Publication type:
- Article
Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1).
- Published in:
- Breast Cancer (13406868), 2023, v. 30, n. 3, p. 412, doi. 10.1007/s12282-023-01436-7
- By:
- Publication type:
- Article
Characterization of protein-based risk signature to predict prognosis and evaluate the tumor immune environment in breast cancer.
- Published in:
- Breast Cancer (13406868), 2023, v. 30, n. 3, p. 424, doi. 10.1007/s12282-023-01435-8
- By:
- Publication type:
- Article
Construction and characterization of a cuproptosis- and immune checkpoint-based LncRNAs signature for breast cancer risk stratification.
- Published in:
- Breast Cancer (13406868), 2023, v. 30, n. 3, p. 393, doi. 10.1007/s12282-023-01434-9
- By:
- Publication type:
- Article
Identification of prognostic genes signature and construction of ceRNA network in pirarubicin treatment of triple-negative breast cancer.
- Published in:
- Breast Cancer (13406868), 2023, v. 30, n. 3, p. 379, doi. 10.1007/s12282-023-01433-w
- By:
- Publication type:
- Article
HER2-positive invasive lobular carcinoma: a rare breast cancer which may not necessarily require anti-HER2 therapy. A population-based study.
- Published in:
- Breast Cancer (13406868), 2023, v. 30, n. 3, p. 343, doi. 10.1007/s12282-022-01432-3
- By:
- Publication type:
- Article
HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC.
- Published in:
- Breast Cancer (13406868), 2023, v. 30, n. 3, p. 364, doi. 10.1007/s12282-022-01431-4
- By:
- Publication type:
- Article
Prognostic effect of subsequent childbirth after the diagnosis of breast cancer using propensity score matching analysis.
- Published in:
- Breast Cancer (13406868), 2023, v. 30, n. 3, p. 354, doi. 10.1007/s12282-022-01429-y
- By:
- Publication type:
- Article